A Phase 3 interventional study of CYB704 and Ocrevus-EU in Relapsing Multiple Sclerosis, sponsored by Sandoz. Active, not recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 7 of the 13 other live ones, and was the 25th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2025.
This study's enrollment of 183 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 27th largest by enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2025, is one of 23 in phase 3, reaches primary completion later than 8 of the 23 other live ones, and was the 98th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R).
The main questions it aims to answer are:
Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CYB704 (Ocrelizumab) Patients will be dosed 300 mg on day 1 and day 15. Subsequent dose of 600 mg will be administered 24 weeks after the initial dose.
Biological: CYB704
Drug: Ocrevus-US/Ocrevus-EU Patients will be dosed 300 mg on day 1 and day 15 with Ocrevus-US. Subsequent dose of 600 mg Ocrevus-EU will be administered 24 weeks after the initial dose.
Biological: Ocrevus-EU · Biological: Ocrevus-US
Intravenous Infusion
Also known as: Ocrelizumab
Intravenous Infusion
Also known as: Ocrelizumab
Intravenous Infusion
Also known as: Ocrelizumab
Area under the concentration time curve
Demonstrate similar PK between Ocrevus and CYB704
Time frame: Week 1 - 3, week 3 - 25
Area under the plasma concentration versus time curve (AUC)
Compare PK between Ocrevus and CYB704
Time frame: Week 1 - 25
Peak Plasma Concentration (Cmax)
Demonstrate similar PK between Ocrevus and CYB704
Time frame: Day 1 and Day 15
CD19+ B-cell count
Compare PD between Ocrevus and CYB704
Time frame: Up to 48 weeks
Number of new T1 GdE lesions on brain MRI scans
Compare efficacy between Ocrevus and CYB704
Time frame: Up to 48 weeks
Number of T1 GdE lesions
Compare efficacy between Ocrevus and CYB704
Time frame: Up to 48 weeks
Number of new/enlarging T2 lesions
Compare efficacy between Ocrevus and CYB704
Time frame: Up to 48 weeks
Number of combined unique active lesions
Compare efficacy between Ocrevus and CYB704
Time frame: Up to 48 weeks
Annualized Relapse Rate
Compare efficacy between Ocrevus and CYB704
Time frame: Up to 48 weeks
Treatment emergent Adverse Events and Serious Adverse Events
Compare safety between Ocrevus and CYB704
Time frame: Up to 48 weeks
Rate of patients with anti-drug antibodies
Compare immunogenicity between Ocrevus and CYB704
Time frame: Up to 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Nov 2026, 16 months.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 16 months is below that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab